Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno Studio di Coorte sulla Sicurezza e l'Efficacia di XH-02 nel Trattamento dell'Ipoparatiroidismo

23 settembre 2026 aggiornato da: Yan Qin, Peking Union Medical College Hospital

Uno Studio di Coorte Ampliato sulla Sicurezza ed Efficacia del Farmaco ad Acido Nucleico mRNA XH-02 nel Trattamento dell'Ipoparatiroidismo Adulto

XH-02 is an mRNA nucleic acid drug that expresses PTH in the body following intravenous or subcutaneous injection, providing PTH replacement therapy for patients with hypoparathyroidism. Previous clinical studies have demonstrated the safety of subcutaneously administered XH-02 in several patients with hypoparathyroidism and have yielded clear efficacy results. This study aims to further validate the safety and efficacy of subcutaneously injected XH-02 in the treatment of hypoparathyroidism in a expanded cohort.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Stimato)

60

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Beijing, Cina, 100730
        • Peking Union Medical College Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 90 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Age ≥18 years, both males and females eligible;
  2. History of postoperative chronic HP or autoimmune, genetic, or idiopathic HP for at least 26 weeks. The diagnosis of HP is established based on the presence of inappropriately low serum PTH levels concurrent with hypocalcemia in the past.
  3. Poorly controlled or intolerant to conventional treatment (calcium and vitamin D) for hypoparathyroidism;
  4. BMI 17-40 kg/m² (inclusive) at screening;
  5. If age ≤25 years, radiographic evidence of epiphyseal closure based on X-ray results of the wrist and palm of the non-dominant hand.

Exclusion Criteria:

  1. Impaired PTH response (pseudohypoparathyroidism), characterized by PTH resistance and elevated PTH levels in the presence of hypocalcemia;
  2. Allergic constitution, or allergy to the investigational drug or polyethylene glycol (PEG)-based drugs;
  3. Any disease other than HP that may affect calcium metabolism, calcium-phosphorus homeostasis, or PTH levels, such as active hyperthyroidism; Paget's disease of bone; severe hypomagnesemia; type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus (HbA1C >9%; HbA1C test results from blood samples collected within 12 weeks prior to screening are acceptable); severe and chronic liver or kidney disease; Cushing's syndrome; multiple myeloma; active pancreatitis; malnutrition; rickets; recent prolonged immobilization; active malignancy (except for low-risk well-differentiated thyroid cancer or non-melanoma skin cancer); active hyperparathyroidism; parathyroid carcinoma occurring within 5 years prior to screening; acromegaly; or multiple endocrine neoplasia;
  4. Pregnant or breastfeeding women;
  5. Male partners with female partners planning to become pregnant, or partners of childbearing potential who are unwilling to use adequate contraceptive methods during the study period;
  6. Patients with high-risk thyroid cancer requiring TSH suppression to <0.2 mIU/L within 2 years, or those with a history of tumors;
  7. Use of loop diuretics, phosphate binders (except calcium supplements), digoxin, lithium, methotrexate, biotin >30 mcg/day, or systemic corticosteroids (except as replacement therapy);
  8. Use of PTH-like drugs (whether commercially available or obtained through participation in clinical trials), including PTH(1-84), PTH(1-34), or other N-terminal fragments or analogs of PTH, or PTH-related protein within 4 weeks prior to screening;
  9. Participation in any other interventional trial receiving investigational drugs or devices within 8 weeks prior to screening, or still within 5.5 half-lives of the investigational drug from the trial in which they participated;
  10. Presence of uncontrolled hypertension at baseline, or a history of the following cardiovascular or cerebrovascular diseases, including: (1) unstable angina; (2) cardiac arrhythmias requiring medication or severe arrhythmias; (3) myocardial infarction; (4) heart failure class III or higher (NYHA classification), second-degree or higher atrioventricular block; (5) cerebral infarction (excluding lacunar infarction), cerebral hemorrhage, or other such diseases;
  11. Increased risk of osteosarcoma, such as having Paget's disease of bone or unexplained elevated alkaline phosphatase, having genetic disorders predisposing to osteosarcoma, or having a prior history of extensive external beam or implant radiation therapy involving bone;
  12. Disease processes that adversely affect gastrointestinal absorption, including but not limited to short bowel syndrome, significant small bowel resection, gastric bypass surgery, tropical sprue, active celiac disease, active ulcerative colitis, active Crohn's disease, gastroparesis, and autoimmune regulator gene mutations associated with malabsorption;
  13. Any medical or other condition that, in the investigator's judgment, may affect the conduct of the study, interfere with the study results, or increase the risk to the subject/study.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Single dose: 40 μg

Participants will receive a single subcutaneous dose of 40 μg of XH-02

Participants will receive a single dose of XH-02 through subcutaneous injection.

Sperimentale: Single dose: 60 μg

Participants will receive a single subcutaneous dose of 60 μg of XH-02

Participants will receive a single dose of XH-02 through subcutaneous injection.

Sperimentale: Single dose: 80 μg

Participants will receive a single subcutaneous dose of 80 μg of XH-02

Participants will receive a single dose of XH-02 through subcutaneous injection.

Sperimentale: Single dose: 120 μg

Participants will receive a single subcutaneous dose of 120 μg of XH-02

Participants will receive a single dose of XH-02 through subcutaneous injection.

Sperimentale: Single dose: 160 μg

Participants will receive a single subcutaneous dose of 160 μg of XH-02

Participants will receive a single dose of XH-02 through subcutaneous injection.

Sperimentale: Multiple dose: 40 μg

Participants will receive 40 μg of XH-02 via subcutaneous injection daily or every other day, for a total of 5 doses.

Participants will receive XH-02 via subcutaneous injection daily or every other day, for a total of 5 doses.

Sperimentale: Multiple dose: 60 μg

Participants will receive 60 μg of XH-02 via subcutaneous injection daily or every other day, for a total of 5 doses.

Participants will receive XH-02 via subcutaneous injection daily or every other day, for a total of 5 doses.

Sperimentale: Multiple dose: 80 μg

Participants will receive 80 μg of XH-02 via subcutaneous injection daily or every other day, for a total of 5 doses.

Participants will receive XH-02 via subcutaneous injection daily or every other day, for a total of 5 doses.

Sperimentale: Multiple dose: 120 μg

Participants will receive 120 μg of XH-02 via subcutaneous injection daily or every other day, for a total of 5 doses.

Participants will receive XH-02 via subcutaneous injection daily or every other day, for a total of 5 doses.

Sperimentale: Multiple dose: 160 μg

Participants will receive 160 μg of XH-02 via subcutaneous injection daily or every other day, for a total of 5 doses.

Participants will receive XH-02 via subcutaneous injection daily or every other day, for a total of 5 doses.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Adverse events (safety)
Lasso di tempo: From the first dose through 30 days after the last dose for non-serious adverse events, and through 3 months after the last dose for severe adverse events.

Adverse events, including serious adverse events. Assessment methods: spontaneous reports; scheduled laboratory tests (hematology, chemistry, C-reactive protein, urinalysis); vital signs (blood pressure, heart rate, respiratory rate, temparature), physical examinations, and electrocardiogram (QTc interval, arrhythmia).

From the first dose through 30 days after the last dose for non-serious adverse events, and through 3 months after the last dose for severe adverse events.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
PTH(1-84) (efficacy)
Lasso di tempo: Single dose: Predose (within one hour before dosing) and 4, 8, 12, 18, 24, 30, 36, 48, 60, and 72 hours postdose. Multiple dose: Predose (within one hour before each dose) and 4, 8, 12, 24, 30, 36, 48, 60, and 72 hours after the last dose.

Serum PTH(1-84)

Single dose: Predose (within one hour before dosing) and 4, 8, 12, 18, 24, 30, 36, 48, 60, and 72 hours postdose. Multiple dose: Predose (within one hour before each dose) and 4, 8, 12, 24, 30, 36, 48, 60, and 72 hours after the last dose.
PTH (efficacy)
Lasso di tempo: Single dose: Predose (within one hour before dosing) and 4, 8, 12, 18, 24, 30, 36, 48, 60, and 72 hours postdose.

Serum PTH

Single dose: Predose (within one hour before dosing) and 4, 8, 12, 18, 24, 30, 36, 48, 60, and 72 hours postdose.
Serum calcium (efficacy)
Lasso di tempo: Single dose: Predose (within one hour before dosing), and 4, 8, 12, 24, 36, 48, and 72 hours postdose. Multiple dose: Predose (within one hour before each dose) and 24, 48, and 72 hours after the last dose.

Serum calcium

Single dose: Predose (within one hour before dosing), and 4, 8, 12, 24, 36, 48, and 72 hours postdose. Multiple dose: Predose (within one hour before each dose) and 24, 48, and 72 hours after the last dose.
Serum phosphorus (efficacy)
Lasso di tempo: Single dose: Predose (within one hour before dosing) and 4, 8, 12, 24, 36, 48, and 72 hours postdose. Multiple dose: Predose (within one hour before each dose) and 24, 48, and 72 hours after the last dose.

Serum phosphorus

Single dose: Predose (within one hour before dosing) and 4, 8, 12, 24, 36, 48, and 72 hours postdose. Multiple dose: Predose (within one hour before each dose) and 24, 48, and 72 hours after the last dose.
Serum magnesium (efficacy)
Lasso di tempo: Single dose: Predose (within one hour before dosing) and 4, 8, 12, 24, 36, 48, and 72 hours postdose. Multiple dose: Predose (within one hour before each dose) and 24, 48, and 72 hours after the last dose.

Serum magnesium

Single dose: Predose (within one hour before dosing) and 4, 8, 12, 24, 36, 48, and 72 hours postdose. Multiple dose: Predose (within one hour before each dose) and 24, 48, and 72 hours after the last dose.
1, 25-Dihydroxyvitamin D3 (efficacy)
Lasso di tempo: Single dose: Predose (within one hour before dosing) and 24, 48, and 72 hours postdose. Multiple dose: Predose (within one hour before the 1st, 3rd, and 5th dose) and 48 hours and 72 hours after the last dose.

Serum 1, 25-Dihydroxyvitamin D3

Single dose: Predose (within one hour before dosing) and 24, 48, and 72 hours postdose. Multiple dose: Predose (within one hour before the 1st, 3rd, and 5th dose) and 48 hours and 72 hours after the last dose.
24-hour urine calcium (efficacy)
Lasso di tempo: Single dose: Predose (within 3 days before dosing), and 24, 48, and 72 hours postdose. Multiple dose: Predose (before each dose) and 24, 48, and 72 hours after the last dose.

24-hour urine calcium (24hUCa)

Single dose: Predose (within 3 days before dosing), and 24, 48, and 72 hours postdose. Multiple dose: Predose (before each dose) and 24, 48, and 72 hours after the last dose.
Fractional Excretion of calcium (efficacy)
Lasso di tempo: Single dose: Predose (within one hour before dosing) and 12, 24, 36, 48, and 72 hours postdose. Multiple dose: Predose (before each dose) and 24, 48, and 72 hours after the last dose.

Fractional Excretion of calcium (FECa)

Single dose: Predose (within one hour before dosing) and 12, 24, 36, 48, and 72 hours postdose. Multiple dose: Predose (before each dose) and 24, 48, and 72 hours after the last dose.

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Procollagen type 1 N-terminal propeptide (Exploratory endpoint)
Lasso di tempo: Multiple dose: Predose (within one hour before each dose) and 24, 48, and 72 hours after the last dose.

Serum Procollagen type 1 N-terminal propeptide (P1NP)

Multiple dose: Predose (within one hour before each dose) and 24, 48, and 72 hours after the last dose.
Beta-isomerized C-terminal telopeptide of type 1 collagen (Exploratory endpoint)
Lasso di tempo: Multiple dose: Predose (within one hour before each dose); and 24, 48, and 72 hours after the last dose.

Serum Beta-isomerized C-terminal telopeptide of type 1 collagen (β-CTX)

Multiple dose: Predose (within one hour before each dose); and 24, 48, and 72 hours after the last dose.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Yan Qin, Peking Union Medical College Hospital

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

13 aprile 2026

Completamento primario (Stimato)

30 aprile 2030

Completamento dello studio (Stimato)

30 luglio 2030

Date di iscrizione allo studio

Primo inviato

13 aprile 2026

Primo inviato che soddisfa i criteri di controllo qualità

13 aprile 2026

Primo Inserito (Effettivo)

20 aprile 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

28 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

23 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

The investigators do not plan to share Individual Participant Data (IPD) due to confidentiality agreements and participant privacy commitments.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi